I agree, it is hard to understand how they can expect revenue when this test is for Leronlimab which is not approved for roughly 6 months from now? Will the revenue come from cytodyn due to testing for trial patients? I really hope there is some further explanation along with some idea of how much revenue etc.. it is very interesting for sure!